BioPort
Executive Summary
Department of Defense renegotiates contract with Lansing, Mich.-based anthrax vaccine manufacturer BioPort, agreeing to pay $10.64 per dose, up from the previous $4.36 per dose (1"The Pink Sheet" July 26, p. 28). BioPort will also manufacture fewer doses, down to 5.3 mil. from 7.6 mil. The value of the new contract, which runs through 2005, is $49.8 mil., compared to $25.7 mil. under the old contract. In addition, DoD has agreed to make an advance payment of $18.7 mil. to the company so that it can pay its creditors
You may also be interested in...
BioPort Anthrax Vaccine Cost To DoD Could Increase, CEO Says
BioPort's price to the Department of Defense for its anthrax vaccine is likely to increase from the current price of about $11, BioPort CEO Robert Kramer told a Senate Appropriations/HHS Subcommittee hearing Oct. 23.
BioPort Anthrax Vaccine Cost To DoD Could Increase, CEO Says
BioPort's price to the Department of Defense for its anthrax vaccine is likely to increase from the current price of about $11, BioPort CEO Robert Kramer told a Senate Appropriations/HHS Subcommittee hearing Oct. 23.
DoD Anthrax Vaccine Program May Need Second Manufacturer, Senators Say
The Department of Defense should consider recruiting a second anthrax vaccine manufacturer to compensate for continued delays experienced by Bioport, Sen. Roberts (R-Kan.) indicated during a Senate Armed Services Committee hearing April 13.